Moteur de recherche d’entreprises européennes
Financement de l’UE (2 629 316 €) : Réseau de recherche translationnelle sur le cancer de la prostate Hor26/09/2016 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Réseau de recherche translationnelle sur le cancer de la prostate
The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer (PC). The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PC, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant PC including castrate-resistant PC (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy. Our research program is built on network-wide, state-of-the-art cancer biology-based mechanistic research integrated with a systems medicine approach: 1. Cancer biology-based mechanistic research incorporating a comprehensive range of model systems incorporating unique, pre-clinical and clinical resources and distinct phenotypic high content screen platforms. 2. A systems medicine approach with mathematical modelling to develop novel predictive/prognostic tools. 3. Centres of excellence in surgery, oncology and clinical trials, comprising clinical infrastructure and essential resources whereby candidate therapeutic targets and predictive/prognostic tools can be comprehensively evaluated, including accessing bio-repository resources. We will train young scientists to apply multiple ‘omics’ technologies and approaches in model systems and systems biology to answer important clinically-relevant questions. Advances achieved will facilitate personalized targeted-medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.
| Cancer Research UK LBG | ? |
| Almac Diagnostic Services Ltd. | 273 288 € |
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | 255 374 € |
| GenomeScan B.V. | 319 218 € |
| Idryma Iatroviologikon Ereunon Akademias Athinon | 242 387 € |
| MOSAIQUES DIAGNOSTICS GmbH | 0,00 € |
| NUMARES AG | 249 216 € |
| TAMPEREEN KORKEAKOULUSAATIO sr | 269 145 € |
| The Queen's University of Belfast | 204 966 € |
| TURUN YLIOPISTO | 269 145 € |
| University of Glasgow | 273 288 € |
| University of Newcastle Upon Tyne | 273 288 € |
https://cordis.europa.eu/project/id/721746
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Cancer Research UK LBG, Londres, Royaume Uni.
Les visualisations de "Cancer Research UK LBG - Financement de l’UE (2 629 316 €) : Réseau de recherche translationnelle sur le cancer de la prostate"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
